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they would avoid medicines unless essential. Only 17% of
subjects suggested they would commence medication at the ﬁrst
sign of symptoms. Delays in seeking treatment up to 3 months
were reported by 26%, 3–6 months by 13% and >6 months by
24% of respondents. The age of symptom onset for those sub-
jects reporting constipation was 14–19 in 17%, 20–29 in 24%,
30–39 in 17%, and >40 in 23%. Eighteen percent of subjects
suggested that some health and personal conditions were too
embarrassing to discuss with their doctor. CONCLUSIONS: The
results are consistent with the opportunity for improving the role
of pharmacy services in managing constipation. Improved service
delivery in this sector might reduce the high proportion (68%)
seeking medical advice for their condition.
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OBJECTIVES: Alginates are often used ﬁrst line for gastroesoph-
ageal reﬂux disease (GORD). In the UK many primary care trusts
(PCTs) believe alginates to be interchangeable and discriminate
between products solely on cost. Consequently several PCTs have
implemented alginate substitution initiatives at the level of the
prescriber in an attempt to save costs. We sought to evaluate
whether PCT guidance suggesting alginate interchangeability
was reﬂected in a large longitudinal representative UK database
by comparing alginate switching patterns. METHODS: IMS
Disease Analyzer data was retrieved in which patients com-
mencing alginate monotherapy were followed for one year from
treatment initiation. From the dataset a cohort of 3367 patients
commencing therapy between June 1, 2005 and May 31, 2006
were tracked following their ﬁrst alginate prescription. Switching
patterns were analysed using chi-square and proportions tests for
the leading alginate brands: Gaviscon Advance (GA) and Peptac.
RESULTS: During the observation period 2238 and 1129 sub-
jects commenced GA and Peptac, respectively. After one year
87% of people on GA compared with 83% on Peptac were
maintained on their initial alginate (p = 0.013). Similar switching
rates were found when excessive switchers, deﬁned as more than
5 different interventions in one year, were removed from the
dataset (p = 0.04). Signiﬁcantly higher proportions of subjects on
Peptac (4%) switched to an alternative alginate compared with
those on GA (2%) (p < 0.005). The frequencies of observed
switching at the end of 12 months was different for those
started on GA and Peptac in the Pearson’s test of independence
(p = 0.039). Furthermore, subjects started on combination GA +
proton pump inhibitor (PPI) were more likely to discontinue PPI
at 12 months compared with those started on Peptac + PPI at
17% and 8%, respectively (p = 0.016). CONCLUSIONS: Sig-
niﬁcant differences in treatment failure were observed for the
leading UK alginates products. Additionally, patients initiated on
GA + PPI were more likely to discontinue their PPI compared
with persons treated with PPI + Peptac. These results highlight
the importance of considering a broader range of costs and
treatment factors impacting patients when introducing product
substitution policies.
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OBJECTIVES: The aim of this study was to gather epidemio-
logical data in a GERD population and to evaluate the added
value of the GERD Impact Scale (GIS) as a useful tool for patient
management of GERD. The GIS (score range 1–4) is a patient
questionnaire designed to aid physicians to identify the appro-
priate treatment and to evaluate the patient’s response to treat-
ment. METHODS: Patients from 296 centers with GERD and
esophagitis grade A to D (LA classiﬁcation) were included. The
physician decided at inclusion whether to initiate or change
the GERD treatment. Patients’ symptoms treatment changes and
GIS were assessed during the study. RESULTS: 2001 patients
(55 years, 52% female, BMI 26 kg/m2) were included. Median
interval between ﬁrst GERD onset and study entry was 1.2 years.
Twenty-ﬁve percent never received any treatment, 25% received
antacids, 25% H2-receptorblockers, 15% had received empiric
PPI therapy and 30% PPI following endoscopy. In 99% of cases,
physicians prescribed PPIs (esomeprazole [82%]) with a daily
dose of 40 mg. The dose was changed to 20 mg at visit 2 in 60%
of patients. The severity of GERD symptoms decreased through-
out the study with 89% of patients having moderate or severe
GERD in visit1, 31% in visit 2 and 14% in visit 3. Concurrently,
the GIS scores decreased signiﬁcantly (-1.18 for upper GI symp-
toms, -1.07 for other related GI symptoms and -0.96 for the
impact on life). GIS scores correlated signiﬁcantly but moderately
with the physician’s clinical judgment and weakly with endos-
copy ﬁndings. GIS was judged useful for 80% of patients. CON-
CLUSIONS: GIS scores improved with GERD PPI treatment and
were judged helpful by the physician. GIS may thus have an
added value over these assessments in determining the appro-
priate treatment and evaluating the patient’s response to this
treatment.
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OBJECTIVES: The aim of this observational study was to gather
epidemiological data not yet available in Luxembourg in a
primary care patient population with GERD with a history of
erosive esophagitis (3 years) and to evaluate the supposed
added value of the GERD Impact Scale (GIS) as a useful tool for
initial and follow-up long-term patient management of GERD.
The GIS (score range 1–4) is a novel patient questionnaire
designed to aid physicians to identify the appropriate treatment
and to evaluate the patient’s response to treatment. METHODS:
Consecutive patients from 20 study centers with symptomatic
GERD with or without esophagitis grade A to D (Los Angeles
classiﬁcation) were included. The physician decided at inclusion
whether to initiate or change the GERD treatment. Exclusion
criteria included current use of proton pump inhibitors (PPIs).
Patients’ symptoms, general evaluation by the physician, treat-
ment changes and GIS were assessed at baseline (visit 1) and
visits 2 and 3 (4–6 weeks and 8–14 weeks, respectively). Analyses
were performed on an intent-to-treat basis. GIS scores were
obtained by the physician at each visit. RESULTS: A total of 142
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patients with visit 2 data available for ITT analysis (152 patients
enrolled) were included (mean age 48 years, 51% female, mean
BMI 27 kg/m2, 75% sedentary lifestyle). Upon inclusion, 21%
had never received any treatment, 44% were receiving, or had
received antacids, 21% H2-receptor blockers, 46% had received
PPI therapy proton pump inhibitors (PPI) therapy (34% omepra-
zole, 31 esomeprazole, 21% pantoprazole, 11% rabeprazole,
3% lansoprazole). After visit 1 physicians changed treatment in
favor of full-dose PPIs (94% of cases), mainly esomeprazole
(75%) and stopped almost all h2-receptors blockers (1%).
Seventy-ﬁve percent of patients were in acute phase treatment
after visit 1 which changed to maintenance treatment phase in
91% of patients after visit 3. There was a concomitant dose
reduction of 40 mg to 20 mg for the most prescribed PPI esome-
prazole. Forty-percent of patients became The prescribed dose
was changed to a median of 20 mg at visit 2 in 32% of patients.
The severity of GERD symptoms decreased substantially
throughout the study with 84% of patients having moderate or
severe GERD in visit 1, 23% in visit 2 and 11% in visit 3.
Concurrently, the GIS scores decreased signiﬁcantly (-1.27 for
upper GI symptoms, -0.92 for other related GI symptoms and
-0.85 for the impact on life; p < 0.001). The GIS was judged to
be helpful for approximately 80% of the patients by the physi-
cians. At all visits, the GIS mean-scores increased markedly with
increasing severity of disease (clinical judgment). The correlation
between GIS mean-scores and endoscopy ﬁndings or the physi-
cian’s judgment of the usefulness of the GIS was less pronounced.
CONCLUSIONS: GIS scores improved with GERD PPI treat-
ment and were judged helpful by the physician. GIS may thus
have an added value over these assessments in determining the
appropriate treatment and evaluating the patient’s response to
this treatment.
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OBJECTIVES: In some European Union countries in recent years
the use of proton pump inhibitors (PPIs) has greatly increased. In
march 2006 in Italy lansoprazole came off patent and became a
relatively cheap treatment. Several national and regional mea-
sures to rationalise PPIs spending growth were taken to promote
the choice of less expensive PPI, lansoprazole, regardless of his
antisecretory potency. The goal of this study was to compare
general practitioners’prescription (GPs) of different PPIs and
explore how GPs PPI prescribing changes following the loss of
lansoprazole patent. METHODS: We extracted all records of PPI
prescribing within a General Practitioner Research Database of
99 GPs located in Naples, Italy, and analysed them using
Microsoft SQL Server 2005. All records for patients who had
been prescribed a PPI were divided into calendar years from 2005
to 2007 (the year prior to and following lansoprazole generic).
PPI consumption were quantiﬁed using Deﬁned Daily Dose
system (DDD). RESULTS: The total volume of PPI’s prescribing
increased steadily over the 3 years. The proportion of deﬁned
daily doses accounted for by lansoprazole was 11.8% in 2005
rising to 35.9% in 2007. The contribution of omeprazole, the
most often PPI prescribed, to total PPIs prescriptions decreased
from 43.0% to 22.7% in the same period, while esomeprazole
contribution remained costant. Following the loss of patent, new
lansoprazole prescriptions increased substantially; 32.7% of sub-
jects switched from another PPI to lansoprazole. CONCLU-
SIONS: To reduce costs GPs have been coming under pressure
encouraging the prescription of a cheaper drug. The wide varia-
tion in PPI prescribing suggests that the choice of PPI by GPs was
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OBJECTIVES: Pathologic deterioration of intervertebral discs,
characterized by annular tears, can cause severe, unremitting low
back pain [LBP] resulting in loss of function and quality of life
for millions of individuals worldwide. Patients experiencing
severe back symptoms beyond six months have poor prognosis
for recovery with conservative management alone. Open surgical
intervention such as spinal fusion and artiﬁcial disc replacement
are being utilized with escalating frequency, however costs and
risks are high. Performed in the outpatient setting, intradiscal
electrothermal therapy [IDET] is minimally invasive, less costly
alternative to surgery for patients nonresponsive to conservative
care. This study prospectively evaluated effectiveness of IDET in
50 consecutive adult patients refractory to conservative care of at
least six months duration. METHODS: Using MRI and dis-
cography to establish internal disc disruption, 50 patients with
lumbar discogenic pain were identiﬁed, underwent IDET treat-
ment and followed for 24 months. Back pain severity (11-point
numeric scale) and back function (Oswestry disability index
[ODI]) were evaluated pre-treatment, 12 and 24 months post-
procedure. Clinical success deﬁned as lack of follow-up surgery,
2-point pain, and 15-point ODI improvement. RESULTS:
Average 68% and 66% improvements in pain and ODI, respec-
tively, between pre-treatment and 24 months (p < 0.0001 for
both comparisons). Global clinical success rate was 78% (39/50).
No complications occurred during IDET procedure. No post-
procedural adverse events such as infections or neurological
sequelae reported. CONCLUSIONS: The signiﬁcant and robust
clinical improvements in function through 24 months and 78%
global success rate achieved in this study compare favorably with
previously published results for IDET using similar patient
selection criteria. Careful patient selection based on discography
and imaging may improve outcomes. Risk of procedure-related
adverse events is low. IDET offers a safe, low-cost treatment
alternative with demonstrated durable, long-term clinical
beneﬁts in the continuum of care of patients with discogenic
LBP.
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OBJECTIVES: To assess the effectiveness and economic conse-
quences for Moscow hospitals of the “ready-to-use” collagen
patch coated with thrombin and ﬁbrinogen—trade name
TachoComb—compared with current haemostatic practice in
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